Videos

Therapeutic Management of Nonmetastatic Prostate Cancer

Therapeutic Approach for Nonmetastatic Prostate Cancer

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.

Managing Relapsed Chronic Myeloid Leukemia

Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the field of melanoma.

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.

Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in patients with glioblastoma.

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses efficacy results for denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).

Tatyana Feldman, MD, John Theurer Cancer Center, Hackensack University Medical Center, discusses the phase III Echelon-1 study, which found brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) demonstrated superior modified progression-free survival (PFS) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma. 

Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

Denise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses the role of enzalutamide in hormone-receptor positive (HR+) advanced breast cancer.

Joshua Richter, MD, Hackensack University Medical Center, discusses a tool which explored the incidence and survival impact of self-reported symptoms and psychologic distress among patients with multiple myeloma during the 2017 ASH Annual Meeting.

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discusses long-term follow-up results for ibrutinib (Imbruvica) in relapsed/refractory mantle cell lymphoma.

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br /> &nbsp;

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).

Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses &nbsp;4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br /> &nbsp;

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.<br /> <br /> &nbsp;